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INTRODUCTION
Leber hereditary optic neuropathy (LHON, MIM535000) is the most 
common illness caused by mitochondrial DNA (mtDNA) muta-
tions, with an estimated prevalence of 1 in 40,000 in Europe.1 In 
95% of LHON cases, the disease is due to point mutations in the 
ND1 (G3460A), ND4 (G11778A), or ND6 (T14484C) genes which 
encode proteins of the respiratory chain complex I (CI); about 70% 
of patients harbor the ND4 mutation.2 CI defect is the direct cause of 
retinal ganglion cell (RGC) loss and optic atrophy.3 There is currently 
no treatment for LHON; even though recent reports described that 
idebenone (an analog of Coenzyme Q10) or EPI-743 (a para-benzo-
quinone) administration partially ameliorate the visual outcome of 
LHON patients.4–6 LHON offers a unique opportunity for gene ther-
apy setting for three reasons: (i) vision loss often occurs in a bilateral 
sequential fashion, the second eye becoming involved after the first 
with a median delay of 2 months,7 thus, a prospect exists for a thera-
peutic intervention after vision loss in the first eye before second eye 
involvement; (ii) drugs or gene therapy vectors may be easily and 
directly delivered to RGCs, by injection into the vitreous body.7,8 Thus, 
we intended to develop a strategy which could be translated to clinic 
research for LHON. Though, the techniques required for introduc-
ing genes directly into mitochondria are scarce yet, consequently, 
direct targeted repair or replacement of mutated mtDNA genes is not 
easy to perform except in yeast using biolistics strategies.9 Progress 
could be obtained with the use of modified AAV vectors which could 
deliver DNA to the organelle as recently reported.10,11 We choose to 
circumvent this barrier by using allotopic expression which is defined 
as a wild-type version of defective mitochondrion-encoded gene is 
delivered via a suitable vector to the nucleus of recipient cells. The 
corresponding mRNA is translated in the cytosol and the protein 
imported into the mitochondrion, where it should complement the 
genetic defect. However, because of the highly hydrophobic nature 
of mitochondrion-encoded proteins,12 several teams were unable 
of fully rescuing respiratory chain dysfunction in cultured cells with 
mtDNA mutations;13–16 despite some reports described satisfactory 
results.17,18 We did benefit from the knowledge, in Saccharomyces 
cerevisiae, on mitochondrial biogenesis and proteome.19 Reports 
on electron microscopy described the presence in the mitochon-
drial outer membrane of specifically attached 80S ribosomes.20 
Biochemical purifications of these ribosomes confirmed that they 
contained mRNAs encoding mitochondrial proteins.21 Moreover, 
biochemical studies established that about 60% of the overall mRNA 
population encoding mitochondrial proteins specifically localized to 
the mitochondrial surface22 and that cis-acting elements in the 5′ and 
3′ of these genes are involved in this specific localization.23 Hence, to 
optimize allotopic expression and guaranty the mitochondrial pro-
tein uptake, we built vectors in which the mtDNA sequences were 
combined with the Mitochondrial Targeting Sequence (MTS) in 5′ and 
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Efficiency of gene therapy with the mitochondrial ND4 gene for optic atrophy
H Cwerman-Thibault et al.
Leber hereditary optic neuropathy is due to mitochondrial DNA mutations; in ~70% of all cases, a point mutation in the mito-
chondrial NADH dehydrogenase subunit 4, ND4, gene leads to central vision loss. We optimized allotopic expression (nuclear 
transcription of a gene that is normally transcribed inside the mitochondria) aimed at designing a gene therapy for ND4; its coding 
sequence was associated with the cis-acting elements of the human COX10 mRNA to allow the efficient mitochondrial delivery of 
the protein. After ocular administration to adult rats of a recombinant adeno-associated viral vector containing the human ND4 
gene, we demonstrated that: (i) the sustained expression of human ND4 did not lead to harmful effects, instead the human protein 
is efficiently imported inside the mitochondria and assembled in respiratory chain complex I; (ii) the presence of the human protein 
in the experimental model of Leber hereditary optic neuropathy significantly prevents retinal ganglion cell degeneration and pre-
serves both complex I function in optic nerves and visual function. Hence, the use of optimized allotopic expression is relevant for 
treating mitochondrial disorders due to mutations in the organelle genome.
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the 3′UTR (UnTranslated Region) of the nuclear COX10 gene. COX10 
mRNA, encoding an inner mitochondrial membrane protein involved 
in heme biosynthesis, is enriched at the surface of the mitochondria 
in human cells.24 Consequently the hybrid mRNA should localize to 
the mitochondrial surface where the translation and the transport are 
tightly coupled.25,26 The beneficial effect of the procedure was dem-
onstrated by the rescue of respiratory chain dysfunction in fibroblasts 
harboring mutations in ATP6, ND1, or ND4 genes.27,28 The extent of 
complex I or V activity restoration was higher when the COX10-3’UTR 
was used in the constructions instead of the poly adenylation signal 
of SV40; this is why we consider the procedure as “optimized” relative 
to the absence of this 3′UTR signal.27 Next, mitochondrial function 
modulation through optimized allotopic expression was confirmed 
in vivo since a rat model of ND4 dysfunction in RGCs was generated 
by electroporation (ELP) of mutant ND4.29 We report here data from 
experiments conducted in three complementary axes aimed at trans-
lating this procedure to the clinic: (i) wild-type human ND4 expression 
driven by an adeno-associated virus type 2 (AAV2/2) vector does not 
cause rat retinal injury, though the lifetime of gene expression was 
up to 12 months; (ii) human ND4 protein produced from the vector 
is assembled in CI; (iii) human ND4 protein is able to prevent CI defi-
ciency and optic atrophy in a LHON rat model.
ReSUlTS
Optimized allotopic expression of the human wild-type ND4 gene 
leads to sustained mRNA and protein accumulation in rat retinas 
without adverse effects on retinal integrity or function
A recombinant AAV2/2 vector harboring the human open reading 
frame of the mitochondrial ND4 gene and the signals allowing the 
efficient mitochondrial translocation of the protein (MTS and 3′UTR 
of the COX10 gene) was obtained (AAV2/2-ND4) (Figure 1a). It has 
been reported the long-term ocular gene transfer without adverse 
effects in mammals (mouse, rat, dog, nonhuman primates) when 
AAV2 vectors were used.30 In addition, the serotype 2 is highly effi-
cient on transducing inner retina, primarily RGCs.31 The question 
arises whether AAV2/2-ND4 administration in the vitreous body of 
rat eyes is able to efficiently transduce RGCs without compromis-
ing retinal function. AAV2/2-ND4 vector was administrated by a 
single injection in the vitreous body of adult rat eyes at different 
doses (Supplementary Table  S1; Supplementary Material)). First, 
we evaluated the transduction efficacy by determining the num-
ber of RGCs which expressed the GFP (gene included in the vec-
tor) in retinal sections from rats euthanized up to 12 months after 
vector administration. A recent report concluded that BRN3A anti-
body staining of radial retinal sections is a preferred method for 
estimating RGC frequency when compared to techniques using 
retinal whole mounts in rodent models of ocular disease.32
When nine independent retinas subjected to AAV2/2-ND4 admin-
istration via intravitreal injection were evaluated 6 months postin-
jection, we found that about 75% of RGCs expressed the transgene 
indicating both efficient and stable transduction with AAV2/2-ND4 
(Supplementary Figure S1). Next, to determine the kinetics of human 
ND4 mRNA appearance, semiquantitative real-time PCR of reverse-
transcribed mRNAs (RT-qPCR) were performed with RNAs purified 
from retinas isolated from eyes subjected to vector administration 
or contralateral untreated eyes (animals were euthanized between 
2 to 16 weeks postinjection). Messenger RNA steady-state levels of 
the mitochondrial ATP6 gene was the most stable in the 60 inde-
pendent samples evaluated. Therefore, it was chosen to normalize 
the mRNA species and to estimate their relative abundance. Human 
ND4 mRNA was detected 2 weeks after vector administration and 
its amount remained stable 14 weeks later (Figure 1b). This result 
may be considered as weak when compared to endogenous ATP6 
mRNA; however the signal obtained by RT-qPCR for each mRNA 
molecule reflected their level in all the retinal cells (~10 millions) 
while human ND4 mRNA accumulated only in transduced RGCs 
representing ~1% of the overall retinal cell population.33 The human 
ND4 transcript was 15.5-fold (Figure 1c) and 331-fold less abundant 
than BRN3A and SNCG mRNAs respectively which encode known 
RGC markers.34,35 The sustained expression of human ND4 did not 
modify the relative abundance of the two transcripts (Figure  1d); 
indeed mRNA levels in treated eyes relative to untreated ones 
were not significantly different (P values: 0.26 for BNR3A and 0.88 
for SNCG). Protein extractions from single retinas were subjected to 
Western blotting analyses to determine the steady-state levels of 
the human ND4 protein in retinas from four treated eyes (6 months 
after treatment), and compared with the abundance of two CI sub-
units (NDUFA9 and NDUFB8) and one complex V subunit (ATP syn-
thase α). The antibody against HA1 epitope (three HA1 epitopes are 
appended at the C-terminal of the human ND4 protein) revealed 
a signal with an apparent molecular mass of ~54 kDa only in reti-
nas from treated eyes (Figure 1e); the predicted size of the human 
ND4 protein, after the cleavage of the COX10 MTS, is about 54 kDa: 
51.7 kDa for the 459 amino acids of ND4 + ~2.7 kDa for the 27 amino 
acids of the 3 HA1 epitopes. The mitochondrial proteins NDUFA9, 
NDUFB8 and ATP synthase α were detected as single bands of 
approximately 39, 19, and 60 kDa (Figure 1e).
To establish whether human ND4 expression could be detrimen-
tal for retinal function or morphology two parameters were evalu-
ated: eye fundus using confocal Scanning Laser Ophthalmoscopy 
(cSLO)36 and optomotor head-tracking responses.37 SLO evalua-
tions allow obtaining images of the nerve fiber layer in which the 
disposition of the nerve bundles in a single plane is well resolved 
because of their cylindrical shape over the pigmented background, 
thus distinguishing individual bundles of RGC axons becomes 
possible.36,38 Evaluations were performed in both eyes from 60 
animals subjected to intravitreal administration of AAV2/2-ND4 
(Supplementary Table S1) at four points’ postinjection (1, 3, 6, and 
9 months). Representative examples of two of animals injected 
with 109 or 1010 VG in their left eyes are shown in Figure 2a. Images 
obtained 3 and 6 months postinjection did not show any difference 
of nerve fiber densities, when compared to those of eyes before vec-
tor administration, indicating that wild-type ND4 expression did not 
lead to noticeable RGC axon disappearance. Next, optomotor head- 
tracking responses were recorded in 30 rats 6 months after AAV2/2-
ND4 administration and in 24-week-old control rats (Figure 2b). 
Three grating frequencies were tested in clockwise and counter-
clockwise directions of motion and responses scored for left eyes 
and right eyes respectively were similar for all of them; thus we 
illustrated those of the 0.25 cycle per degree frequency (Figure 2b). 
Control rats mostly presented head tracking responses of similar 
magnitude for the clockwise (LE) or counterclockwise (RE) drum 
rotations (P = 0.58). Scores recorded in rats subjected to AAV2/2-
ND4 administration were similar to control rat responses (P = 0.76 
and 0.79 for clockwise motion and 109 and 1010 VG respectively). 
Therefore, long-term human ND4 expression did not lead to delete-
rious effects on optic fiber densities or visual function.
Human ND4 protein localizes to rat RGC mitochondria and 
interacts with respiratory chain complex I proteins
The subcellular distribution of the human ND4 protein was exam-
ined by immunohistochemistry using antibodies against BRN3A 
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and the HA1 epitope in retinal sections from six rats euthanized 
3–6 months after AAV2/2-ND4 administration. We observed RGC-
positive signal for the anti-HA1 antibody; furthermore, the immu-
noreactivity was often revealed as a punctuate distribution of 
fluorescent dots excluded from the nuclei which could represent 
mitochondria (Figure 3a). To confirm the localization of the human 
ND4 in the mitochondrial compartment, antibodies against the 
mitochondrial protein ND6 (a CI subunit) and the HA1 epitope were 
combined (Figure 3b). Several cells within the ganglion cell layer 
(GCL) were intensely labeled in the cytoplasm, signals appeared 
Figure 1  AAV2/2-ND4 transduction of rat retinas. (a) Physical map of the AAV2/2-ND4 vector genome (7792 bp), encompassing human ND4 sequence 
inserted into the pAAV-IRES-hrGFP plasmid: the ND4 ORF (1377 bp), encoding 459 amino acids (YP_003024035.1), is in frame at the N-terminal with the 
first 28 amino acids (84 bp) of human COX10 and C-terminal with three HA1 epitopes (90 bp) and transcribed under the control of the Cytomegalovirus 
(CMV) promoter and the β-globin intron. The construction contains at the 3’ the untranslated region (603 bp) of the human COX10 mRNA (NM_001303.3). 
The sequences are flanked by inverted terminal repeats (ITRs) that contain all the cis-acting elements necessary for replication and packaging of the AAV2/2 
vector. (b) RT-qPCR assays were performed with total RNAs from retinas (isolated at different times after 5 × 109 VG/eye intravitreal injection of AAV2/2-
ND4) to determine relative abundance of human ND4 mRNA. The kinetics of the human ND4 mRNA apparition was determined between 2 and 16 weeks 
after intravitreal injection; values shown correspond to the normalization of the human ND4 mRNA signal against the ATP6 mRNA signal; seven to eight 
independent RNA preparations per time-post injection were assessed. (c) The relative abundance of human ND4 and BRN3A mRNAs was compared in 
treated eyes which implies the normalization of BRN3A and human ND4 signals with the mean of the signals obtained for the BRN3A mRNA (30 independent 
results were represented). (d) BRN3A and SNCG mRNA abundances were evaluated in 30 treated eyes relative to their contralateral untreated eyes; values 
were normalized against means obtained in the untreated eyes per mRNA evaluated. No significant difference was evidenced between treated and 
untreated retinas; P values were 0.58 and 0.89 for BRN3A and SNCG mRNAs respectively. (e) Representative Western blots from retinas of untreated eyes and 
retinas which eyes were subjected to AAV2/2-ND4 administration (5 × 109 VG); rats were euthanized 6 months after vector administration. Four independent 
extractions from treated and untreated retinas were evaluated. Each western blot was performed two to four times, and the following antibodies were 
sequentially used: anti-HA1, anti-NDUFA9, anti-NDUFB8, anti-ATP synthase α and anti-β-actin. The anti-HA1 antibody revealed a signal of approximate 
~54 kDa only in treated retinas which may correspond to the human ND4 protein. The “PageRuler Plus Prestained Protein Ladder” allowed the estimation 
of apparent molecular mass of each signal; in the margin of each autoradiogram are annotated the recombinant proteins from the ladder with similar 
electrophoretic properties than the ones revealed in the membrane after Western blotting (proteins spanning 15–70 kDa).
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as punctuate fluorescent dots excluded from the nuclei with both 
antibodies indicating some extent of colocalization between the 
two proteins. In Figure 3b, the merge of the images illustrates 
yellow-orange pixels corresponding to the regions in which both 
proteins appear to be apposed (white arrowheads) within the same 
cells. This suggests that human ND4 proteins synthesized from the 
AAV2/2-ND4 vector localize to the mitochondria.
To determine whether the human ND4 protein is assembled in 
respiratory chain CI, three pairs of independent retinal sections from 
eyes transduced with AAV2/2-ND4 and their untreated counterparts 
were subjected to in situ Proximity Ligation Assay (PLA), which was 
reported as efficient to prove that two proteins are positioned 
within close proximity (<40 nm) of each other allows visualization 
of protein interactions in fixed tissues.39 Moreover, the reliability of 
the technique for demonstrating protein interactions was proven 
in rodent retinal sections.40–42 For the assay, antibodies against 
proteins which localize to different mitochondrial compartments 
were used: five inner membrane proteins: OPA1, SDHA1, ND6, 
NDUFB6, and NDUFS1 and two outer membrane proteins: VDAC 
and TOMM20. OPA1 is essential for preserving organelle dynam-
ics43 and was described as interacting with the 70-kDa (FP) subunit 
of complex II protein, SDHA1.44 ND6, NDUFB6, and NDUFS1 are CI 
subunits; CI is a L-shaped complex consisting of two perpendicular 
arms: a hydrophobic arm which resides in the inner membrane and 
a hydrophilic peripheral arm which projects into the matrix; ND4, 
ND6, and NDUFB6 localize to the membrane while NDUFS1 resides 
in the hydrophilic arm.45 It clearly appears that ND4-HA1 interacts 
with ND6 and NDUFS1, since numerous bright red dots suggestive 
of closely apposed binding of the antibodies were observed; the 
overall responses for the HA1 antibody were comparable to those 
obtained for NDUFB6/ND6 and NDUFB6/NDUFS1 antibody combi-
nations (Figure 4a). Fluorescent signals were particularly apparent 
in the GCL and also in the inner plexiform layer (IPL) which contains 
RGC dendrites and bipolar cell axons. Very weak signal was detected 
when anti-NDUFB6 or anti-HA1 antibodies were combined with 
anti-VDAC or anti-OPA1 antibodies; these results are indicators for 
a non-existing interaction between: NDUFB6 and VDAC, NDUFB6 
and OPA1, ND4-HA1 and VDAC, ND4-HA1 and OPA1. In contrast, 
abundant fluorescent spots were detected when the assay was 
performed with anti-OPA1 and anti-SDHA1 antibodies (Figure 4a,b) 
confirming that these two proteins are located in close proxim-
ity in vivo as reported in human fibroblasts in which OPA1 was 
shown to physically interacts with the 70-kDa (FP) subunit of com-
plex II (i.e., SDHA1) when immunoprecipitation experiments were 
performed.44 Importantly, when retinal sections from untreated 
eyes were assessed using the anti-HA1 antibody, no staining was 
detected supporting the specificity of the signal in retinal sections 
from treated eyes (Figure 4b). Hence, these data indicate that the 
human protein ND4 is present in RGC mitochondria and either 
physically interacts with ND6 and NDUFS1 or the distance between 
these three proteins is shorter than 40 nm; strongly suggesting the 
presence of the human ND4 protein within CI.
Subsequently, we performed Blue Native-PolyAcrylamide Gel 
Electrophoresis (BN-PAGE) which results in the optimal separation 
of mitochondrial respiratory chain complexes in their native form, 
thus allowing to demonstrate whether a protein resides within one 
Figure 2 Morphological and functional in vivo evaluation of adult rats after ocular administration of AAV2/2-ND4. (a) Eight-week-old rats were subjected 
to injection with different doses of the AAV2/2-ND4 vector (Supplementary Table S1) in the vitreous body of their left eyes. Twelve animals were 
evaluated for each dose using a cSLO at different points post-injection. Images shown were taken 3 and 6 months after vector administration; eyes 
before the intervention are also shown (left panel). No change was noticed in nerve fiber density after AAV2/2-ND4 administration (1 × 109 or 1 × 1010 
VG). (b) Three different groups of rats were evaluated for head tracking movements in photopic conditions. No significant difference was observed in 
any of the 30 animals examined in both clockwise (LE) and counterclockwise (RE) directions of motion when the AAV2/2-ND4 was administrated at two 
different doses (1 × 109 and 1 × 1010 VG/left eye). Their optomotor behavior was identical to the one elicited in control rats.
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of them.46 Four independent homogenates obtained by combining 
eight retinas from untreated eyes or eyes transduced with AAV2/2-
ND4 were collected from rats euthanized 3–6 months after vector 
administration, subjected to two-dimensional blue native/SDS elec-
trophoresis and revealed with specific antibodies against different 
respiratory chain complex subunits. Figure 5 shows a specific signal 
when the anti-HA1 antibody was used; the signal was not detected 
in homogenates from untreated eyes. The specific band evidenced 
with anti-HA1 antibody migrates slightly slower than NDUFA9 (the-
oretical molecular mass of 39 kDa) as illustrated (merge between 
the two autoradiograms, Figure 5, right panel). The putative human 
ND4 protein migrates similarly to the UQCRC1 subunit of complex 
III which theoretical molecular mass is ~53 kDa; confirming data 
obtained with retinal protein extracts (Figure 1e). Indeed, the dis-
tance which separates signals from antibodies against NDUFA9 and 
HA1 epitopes is almost identical than the one which separates sig-
nals from antibodies against NDUFA9 and UQCRC1 (Figure 5, bot-
tom panel). Moreover, the anti-HA1 antibody signal was revealed 
on the same vertical line than NDUFA9, NDUFB8, and NDUFS1. 
Therefore, the human ND4 protein comigrates with three CI sub-
units reinforcing the idea that the human ND4 protein is correctly 
assembled in CI.
Long-lasting expression of the human ND4 gene in retinas from 
rats mimicking LHON
The ocular administration of the human ND4 gene harboring the 
G11778A mutation via in vivo electroporation (ELP) leads to RGC 
loss, optic atrophy and visual function impairment about 30 days 
after the intervention in adult rats.29 To demonstrate that AAV2/2-
ND4 is efficient on preventing RGC dysfunction in vivo, we first 
chose the procedure which better resembles the clinical situation. 
About 70% of LHON patients bear the G11778A mutation (ND4 
gene) in all the mtDNA molecules of the body.2 At one moment 
of patient’s life mitochondrial impairment reaches a threshold in 
which RGCs, unable to ensure their function, degenerate leading to 
central vision loss.2,7 In the LHON model we previously described, 
the coexistence of human ND4 protein with the R340H substitution, 
Figure 3 Expression of human ND4 protein in rat retinas. Retinal sections from six independent eyes transduced with AAV2/2-ND4 (5 × 109 VG/eye) 
were obtained 3–6 months postinjection. Nuclei were stained with DAPI (blue); GCL represents the ganglion cell layer and scale bars are 20 µm for all 
panels shown. (a) Immunostaining of retinal sections from eyes transduced with AAV2/2-ND4 (5 × 109 VG/eye) was performed with antibodies against 
the nuclear factor BRN3A (green) and the HA1 epitope (red); the contralateral untreated eye was used as negative control. (b) Retinal sections were 
double labeled for the mitochondrial ND6 protein (green) and the anti-HA1 epitope (red); images for two treated-eyes and one untreated-eye are 
illustrated. The yellow-orange pixels (ND6 + ND4-HA1 panel) show that ND6 and ND4-HA1 were in close apposition in some cells (white arrowheads).
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encoded by the nuclear version of the human ND4 gene carrying 
the G11778A mutation, and the endogenous ND4 protein did not 
engender deleterious effects on RGCs within the first 14 days after 
in vivo ELP.29 Therefore, 8-week-old rats were subjected to ELP with 
mutant ND4 and ten days later, a single intravitreal injection in the 
electroporated eye was performed with AAV2/2-ND4 or AAV2/2-
GFP. Evidently, AAV2/2-GFP administration is not expected to coun-
teract the mutant ND4 effect, neither to induce in vivo toxicity.47 This 
protocol should allow to seek after AAV2/2-ND4 ability to protect 
RGCs: when vector is administrated, mutant ND4 expression driven 
by ELP was already started29 and human ND4 mRNA accumulates in 
transduced RGCs about 2 weeks after vector administration (Figure 
1b). First, we determined the AAV2/2 transduction efficiency when 
performed after ELP compared to a single AAV2/2 injection. The 
overall number of RGCs which were immunolabeled for the GFP 
in five independent retinal sections was 74.4%; hence, the efficacy 
of RGC transduction by AAV2/2-ND4 did not change when rat eyes 
were first subjected to ELP (Supplementary Figure S1). The presence 
of human ND4 mRNA in retinas from treated eyes was determined 
by RT-qPCR. Animals were euthanized 10–12 months after vector 
administration and RNA preparations from retinas of 15 untreated 
eyes and 15 eyes subjected to ELP with mutant ND4 and intravit-
real injection of AAV2/2-ND4 (109 VG or 1010 VG) were examined. 
Human ND4 mRNA was exclusively detected in treated eyes; its rela-
tive amount in these retinas was comparable to the one measured 
in retinas isolated 4 months after a single AAV2/2-ND4 intravitreal 
injection, Figure 1b (P = 0.21), confirming a sustained transgene 
expression overtime (Figure 6a). Besides, human ND4 mRNA abun-
dance relative to BRN3A was about 15-fold lower (Figure 6b) as 
shown after a single intravitreal AAV2/2-ND4 injection (Figure 1c). 
Next, RNA preparations from retinas of 12 eyes transduced with 
mutant ND4 via ELP and subjected 10 days later to an intravitreal 
injection of AAV2/2-GFP were evaluated. A 15% reduction in SNCG 
and BRN3A mRNA steady-state levels was measured when RNA 
preparations from untreated and treated retinas were compared 
(Figure 6c; P = 0.0011 and 0.0003 respectively). This diminution 
reveals AAV2/2-GFP inability to counteract the deleterious effect of 
mutant ND4 expression on RGC integrity. Conversely, the relative 
abundance of BRN3A and SNCG mRNAs was not significantly dif-
ferent between untreated eyes and eyes from the LHON model 
expressing the human ND4 gene; P values were 0.54 and 0.7 respec-
tively (Figure 6d). Therefore, AAV2/2-ND4 administration hindered 
RGC loss induced by mutant ND4 expression.
Effect of AAV2/2-ND4 treatment on RGC and optic fiber integrity in 
the LHON model
Eye fundus was performed using cSLO to follow optic fiber integ-
rity in treated eyes. Representative examples are shown in Figure 
7a; the eye electroporated with mutant ND4 and 10 days later 
transduced with AAV2/2-GFP shows a severe loss of optic fibers 
which corresponds to almost half of the examined area (Figure 7a). 
Figure 4 In situ PLA analysis of retinal sections from eyes expressing human ND4. Retinal sections from three independent eyes treated with AAV2/2-
ND4 or their partner untreated eyes were subjected to in situ PLA analysis; the human ND4 protein was revealed using a monoclonal antibody against 
the HA1 epitope. PLA signals are red and the nuclei stained with DAPI are blue; scale bars correspond to 25 µm. GCL, ganglion cell layer; INL, inner 
nuclear layer. (a) Several combinations of antibodies were tested in retinal sections from eyes subjected to AAV2/2-ND4 administration. The antibody 
against HA1 epitope (ND4-HA1) gave strong positive signals when combined with antibodies against ND6 and NDUFS1. No interaction between ND4-
HA1 with VDAC or OPA1 protein was inferred by the assay while a strong signal was noticed when antibodies against OPA1 and SDHA1 (70-kDa subunit 
of complex II) were combined. (b) Retinal sections from the untreated eyes were also subjected to the assay. Very weak fluorescence was noticed when 
the anti-HA1 antibody was used confirming that in treated eyes, signal evidenced corresponded to the human ND4 protein. For all other antibody 
combinations the results were similar to those obtained in treated eyes.
ND4-HA1 + ND6 ND4-HA1 + VDAC ND4-HA1 + OPA1 ND4-HA1 + NDUFS1
ND4-HA1 + ND6 ND4-HA1 + VDACND4-HA1 + OPA1ND4-HA1 + NDUFS1
NDUFB6 + ND6 SDHA + OPA1NDUFB6 + OPA1NDUFB6 + NDUFS1
SDHA1 + OPA1
NDUFB6 + ND6 NDUFB6 + VDAC NDUFB6 + OPA1
Eye treated with AAV2/2-ND4 (5 × 109 VG)
Control eye
NDUFB6 + NDUFS1 TOMM20 + NDUFS1
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The disappearance was generally noticed about 6 weeks after ELP; 
two times post-AAV2/2 injection are illustrated (3 and 6 months). 
Out of the 18 eyes evaluated in this group, significant reduction 
in optic fiber density was evidenced in 6 eyes; by contrast, no 
RGC axons loss was observed in 52/54 of the animal eyes which 
were injected with different doses of AAV2/2-ND4 (Supplementary 
Table  S1). The imaging of one of those animals eye fundus 
showed that the tracks of RGC axons were well preserved 3 and 
6 months after vector administration (Figure 7a). To further con-
firm these results transversal optic nerves (ONs) sections from 
the two animals shown in Figure 7a, euthanized 6 months after 
vector administration, were subjected to immunohistochemistry 
for the heavy chain subunit of neurofilaments (NF200) to detect 
RGC axonal profiles. Figure 7b illustrates a recognizable reduc-
tion of immunopositive dots in the ON from the animal in which 
the eye was treated with mutant ND4 and AAV2/2-GFP relative to 
one ON isolated from an age-matched control rat or to the ON 
from the rat illustrated in Figure 7a in which the eye was treated 
with mutant ND4 and AAV2/2-ND4. Since RGC axon number was 
diminished in eyes electroporated with mutant ND4 and treated 
with AAV2/2-GFP, we next estimated RGC number in retinal flat 
mounts immunostained for BRN3A. Figure 7c shows retinas from 
untreated eyes and eyes transduced with mutant ND4 and subse-
quently treated with AAV2/2-GFP or AAV2/2-ND4. Mean RGC count 
per mm2 ± SEM for 26 retinal flat mounts isolated from untreated 
eyes was 1796 ± 26.8. These values are similar to those previously 
described.33 In contrast, average RGC densities for eight eyes 
expressing mutant ND4 and subjected to AAV2/2-GFP injection 
was 1213 ± 35.7 (Figure 7d); a 33% reduction relative to control 
retinas. RGC count difference between these two groups was sig-
nificant (P < 0.0001). Conversely, when retinas from eyes express-
ing mutant ND4 and transduced with AAV2/2-ND4 were evaluated 
a significant protection of the overall RGC density was observed 
(Figure 7d). The mean of RGC counts per mm2 was 1741 ± 51.8 
(97% of the control value), this number was not significantly differ-
ent to the one measured in control retinas (P = 0.24). Hence, RGC 
degeneration due to mutant ND4 expression protein is efficiently 
prevented by AAV2/2-ND4 administration.
Figure 5 Blue native polyacrylamide gel electrophoresis. Four homogenates (eight pooled retinas) from untreated-eyes or eyes subjected to a single 
intravitreal injection with AAV2/2-ND4 were tested with different antibodies (Supplementary Table S2). 2D BN-PAGE of the mitochondrial enriched 
fractions were subjected to western blotting with antibodies against NDUFA9, NDUFB8 and NDUFS1 proteins of CI, UQCRC1 (CIII) and the HA1 epitope. 
In the right the superposition of autoradiograms obtained after anti-HA1 and anti-NDUFA9 antibody incubation and in the bottom the superposition 
for anti-NDUFA9 and anti-UQCRC1 autoradiograms.
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Impairment of visual function in the LHON model is prevented by 
AAV2/2-ND4 treatment
To examine the impact of human ND4 expression in the LHON rat 
model at the functional level, we performed head-tracking experi-
ments to discriminate sensitivities of right eyes or left eyes in the 
LHON model. We evaluated rats transduced with mutant ND4 
in their left eyes and 10 days later subjected to a single intravit-
real injection, in the same eye, with AAV2/2-GFP or AAV2/2-ND4. 
Optomotor responses of these groups were compared to head 
tracking scores for the left or right eyes of 24-week-old control 
rats (Figure 2). Left eye scores were significantly reduced in ani-
mals treated with AAV2/2-GFP (40% of right eye responses); they 
were statistically different to responses recorded for the left eyes 
in control rats (P < 0.0001) indicating that visual performance of 
eyes expressing mutant ND4 was compromised. On the other hand, 
animals which received AAV2/2-ND4 mostly presented head track-
ing scores of similar magnitude for each of their eyes (P = 0.4). The 
scores recorded for the left eyes, in the 30 rats evaluated, were simi-
lar to control rats (P = 0.8). Hence, the salutary impact of AAV2/2-
ND4 administration on nerve fiber integrity (Figure 7a,b) was con-
firmed by the sustained visual function protection evidenced in the 
AAV2/2-ND4 treated eyes.
Respiratory chain complex I activity was preserved in optic nerves 
from LHON rats when eyes were treated with AAV2/2-ND4
To demonstrate that “optimized allotopic expression” of ND4 is 
efficient in vivo besides the strong indication on the presence 
of the human ND4 protein within CI (Figures 4 and 5), it is also 
required setting a robust and reliable assay for CI enzymatic 
activity. We exploit a spectrophotometric method which allows 
the sequential evaluation of the enzymatic activities of CI (NADH 
decylubiquinone reductase) and CV (ATP hydrolase) on a single 
rodent ON.48 The sequential evaluation of CI and CV enzymatic 
activities allowed also CI/CV ratio determination; an accurate 
parameter for detecting an impairment of respiratory chain 
activity.49 Animals were euthanized between 8 and 12 months 
after AAV2/2 injection. CI and CV activities were assessed in four 
groups: (i) 84 ONs from untreated eyes; (ii) 30 ONs from eyes sub-
jected to a single AAV2/2-ND4 intravitreal injection; (iii) 12 ONs 
from animals injected with AAV2/2-GFP (3 × 109 VG) after mutant 
ND4 transduction via ELP; (iv) 26 ONs from animals injected with 
AAV2/2-ND4 after mutant ND4 transduction via ELP. CV activity 
did not change in any of the groups evaluated when compared to 
values assessed in control ONs (Figure 8b). The long-term expres-
sion of human wild-type ND4 gene driven by a single AAV2/2 
Figure 6 Sustained expression of the human ND4 gene in the LHON model. RT-qPCRs were performed with: (i) 15 eyes subjected to mutant ND4 
transduction, via ELP, and 10 days later to AAV2/2-ND4 administration; (ii) 12 eyes subjected to mutant ND4 transduction via ELP and 10 days later 
to AAV2/2-GFP administration. As controls, all the contralateral untreated-eyes were evaluated; animals were euthanized between 8 and 12 months 
after vector administration. (a) Human ND4 mRNA relative abundance in: (i) eight retinas from eyes subjected to a single AAV2/2-ND4 injection in the 
vitreous body (rats were euthanized 4 months later) and (ii) 15 retinas from eyes subjected to mutant ND4 transduction, via ELP, and 10 days later to 
AAV2/2-ND4 intravitreal injection. (b) mRNA abundance relative to BRN3A mRNA abundance in 15 RNA preparations from retinas which eyes which 
received AAV2/2-ND4 by intravitreal injection 10 days after mutant ND4 transduction. (c and d) BRN3A and SNCG mRNA amounts were compared in 
RNA preparations from the LHON model: ELP (mutant ND4) + AAV2/2-GFP or the LHON model in which protection was investigated: ELP (mutant ND4) 
+ AAV2/2-ND4. Transcript abundance variations are represented relative to the means of values assessed in RNAs from untreated retinas.
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Figure 7 Effect of AAV2/2-ND4 on RGC and optic fiber integrity in the LHON model. (a) cSLO fundus imaging of two rat eyes: one subjected to ELP 
(mutant ND4) + AAV2/2-GFP (3 × 109 VG, left panel) and one subjected to ELP (mutant ND4) + AAV2/2-ND4 (5 × 109 VG, right panel) as well as the partner 
untreated-eyes. Images were taken 3 and 6 months after vector administration; yellow discontinued lines show the region with nerve fiber loss in the 
eye treated with AAV2/2-GFP. (b) Proximal ON transversal sections were immunostained with an antibody against NF200 (red); they were obtained from: 
four rats subjected to intravitreal injection with mutant ND4-DNA followed by ELP and 10 days later to another intravitreal injection with AAV2/2-GFP 
(3 × 109 VG) in the same eye; four rats subjected to intravitreal injection with mutant ND4-DNA followed by ELP and 10 days later to another intravitreal 
injection with AAV2/2-ND4 (5 × 109 VG in the same eye) and four age-matched controls. Images shown correspond to ONs from the two animals from 
which eye fundus imaging were illustrated in panel a. Two different magnifications are shown; scale bars represent 200 µm (left panel) and 25 µm (right 
panel). The reduction in optic fiber density was evidenced in all the four ON sections evaluated out of the six animals in which eye fundus imaging 
revealed optic fiber loss. In the contrary, the four ON sections evaluated from eyes treated with AAV2/2-ND4 gave results similar to those observed in 
ONs from age-matched controls. (c) Retinal flat mounts obtained from animals sacrificed 6 months after vector administration were immunolabeled 
for BRN3A antibody (red). Images of two distinct retinal regions are illustrated for: (i) an untreated retina; (ii) an eye subjected to ELP (mutant ND4) + 
AAV2/2-GFP, and (iii) an eye subjected to ELP (mutant ND4) + AAV2/2-ND4; the scale bar corresponds to 25 µm. (d) Histogram shows the means of RGC 
number/mm2 ± SEM obtained after all the BRN3A-positive cells were counted in the three groups evaluated.
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intravitreal injection was safe for CI function (Figure 8c,d); since 
no significant difference was observed when CI or CI/CV values 
were compared to those measured in control ONs (P value was 
0.92 or 0.25 respectively). On the contrary, mutant ND4 expres-
sion led to CI defect in ONs from eyes treated with AAV2/2-GFP 
after in vivo ELP with mutant ND4 (Figure 8c,d); the reduction of 
about 40% relative to untreated eyes was significant (P <0.0001 
for either specific CI activity or CI/CV ratio). Furthermore, AAV2/2-
ND4 was efficient on protecting CI function; indeed CI activity or 
CI/CV ratios was not statistically different from values obtained in 
ONs from untreated eyes: P values were 0.7 and 0.98 respectively 
(Figure 8c,d). Thus, at the molecular level the human ND4 protein 
largely hindered the deleterious effect of mutant ND4 expression 
by preserving CI activity.
DISCUSSION
The first evidence that mitochondrial impairment yields to human 
disease was described in 1962.50 In 1988, it was demonstrated that 
mtDNA deletions were present in the muscle of people suffering 
from mitochondrial myopathy,51 and that a mtDNA mutation was 
responsible for LHON.52 Up to date molecular defects observed in 
both mtDNA-encoded and nuclear DNA-encoded genes of mito-
chondrial proteins are associated with a wide spectrum of clinical 
problems8,53 including myopathy, encephalomyopathy, gastroin-
testinal syndromes, dystonia, diabetes, blindness, deafness, and 
cardiomyopathy. Therefore, mitochondrial disorders represent a 
common cause of chronic morbidity and are more prevalent than 
previously thought; indeed they affect at least 1 in 5,000 indi-
viduals.54 Nevertheless, mitochondrial medicine only made slow 
Figure 8 Assessment of visual function and complex I activity in LHON rats. (a) Visual behavior was evaluated with the optomotor test in four 
groups of animals: (i) 14 control rats (24 weeks of age); (ii) 15 animals transduced with mutant ND4-DNA via ELP + AAV2/2-GFP (3 × 109 VG); (iii) 
15 animals transduced with mutant ND4-DNA via ELP + AAV2/2-ND4 (5 × 108 VG); (iv) 24 animals transduced with AAV2/2-mutant ND4 (5 × 109 
VG). Values presented are expressed as the mean of head tracking per minute (in seconds) ± SEM for each group (spatial frequency of 0.25 cycle 
per degree). Animals were subjected to the test 6 and 9 months after vector administration. Results obtained for groups 3 and 4 were almost 
identical, therefore, they were combined and illustrated as a single group (n = 30). Respiratory chain CI and CV activities were assessed by 
spectrophotometry in single ONs, from animals euthanized 8–12 months after intravitreal injection, ONs were isolated from: (i) 84 untreated 
eyes (controls); (ii) 30 eyes subjected to intravitreal injection with the AAV2/2 harboring the wild-type ND4 gene (AAV2/2-WT-ND4), two doses 
evaluated (5 × 108 VG and 5 × 109 VG) gave similar results, and are illustrated as a single group; (iii) 12 eyes subjected to mutant ND4 transduction 
via ELP + AAV2/2-GFP (negative control); and (iv) 26 eyes subjected to mutant ND4 transduction via ELP + AAV2/2-ND4, two doses evaluated 
(5 × 108 VG and 5 × 109 VG) gave similar results, and are illustrated as a single group. Respiratory chain CI and CV activities are expressed as 
nanomoles of oxidized NADH/min/mg protein. (b) CV activity measurements were shown, no difference was observed between ONs from treated 
eyes relative to controls; P values for groups 2–5 were respectively: 0.17, 0.94, 0.46, and 0.18. (c and d) Histograms representing the CI/CV activity 
ratios and specific CI in the samples evaluated clearly confirm the reduction of CI activity in ONs from eyes subjected to mutant ND4 transduction; 
the reduction was efficiently prevented by AAV2/2-ND4 administration. CI - CV, complexes I and V of the respiratory chain; CI/CV, activity ratio of 
CI for CV; each enzymatic activity was measured in triplicates and illustrated as means ± SEM.
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progress towards effective treatment of these devastating diseases; 
a recent review encompassing 1,335 reports and 12 randomized 
controlled treatment trials in mitochondrial diseases, did not find 
a clear evidence supporting the efficacy of any of these interven-
tions.55 Hence, our main objective was to develop a gene therapy 
that could prevent optic atrophy due to mitochondrial dysfunc-
tion. In this pursuit, we have focused our interest on the LHON 
disease due to the G11778A mutation on the mitochondrial ND4 
gene, since its accounts for 60-90% of LHON cases worldwide2 
with less than 20% chance of recovery.7 Clinical manifestations in 
LHON patients are very peculiar; indeed about 75% of them present 
sequential visual loss in each eye, with the interval between the first 
and second eye involvement ranging from weeks to 2–4 months.7 
This opportunity along with the evidence that gene therapy is well 
tolerated and efficient in Leber Congenital Aumorosis56 has great 
potential for a generalization to mitochondrial disorders specially 
devastating neurodegenerative diseases.53
However, an array of obstacles needs to be overcome before 
being able to offer a clinical protocol safe and beneficial to patients 
harboring mtDNA mutations. The greatest difficulties are: (i) the 
scarcity of reliable experimental models of the disease required 
for the validation of gene therapy or pharmacological approaches 
in  vivo. In this respect, a report of Dr. Wallace and colleagues 
is very promising since it describes the generation of a mouse 
model with the G13997A mutation in the ND6 gene, leading to 
an amino acid substitution (P25L), reported in an optic atrophy 
and Leigh syndrome family57; the mice exhibit some of the LHON 
hallmarks, especially optic atrophy;58 (ii) inserting genetic mate-
rial directly into mtDNA is up to date a difficult task; the reports of 
J. Guy and colleagues in which the modification of an AAV vector 
leads to the expression of the transgene inside the mitochondria 
could allow progress in this pathway10,11; (iii) the efficacy of allo-
topic expression in vivo is still under debate. Several reports since 
2002 provided  controversial results in vitro, in which authors indi-
cated that mitochondria behavior in cultured cells can give a false 
impression on allotopic expression achievement.14–16 For instance, 
Perales-Clemente’s et al.15 claimed a potential generalization of their 
data on unsuccessful allotopic expression, because in a mouse cell 
line, in which wild-type mtDNA was <10%, respiratory chain dys-
function rescue was due to the artefactual selection of revertants 
from the mutated gene. However authors did not prove this state-
ment; indeed these cells when transduced with any kind of vector 
should be equally able to drive CI assembly. Moreover, independent 
groups worldwide did show unambiguously that allotopic expres-
sion results on the functionality of the protein within the mito-
chondria in mice and rats,29,59–63 and in cancer cells.64 Additionally, 
it was reported the generation of transgenic mice for wild-type or 
a mutated version of the mitochondrial ATP6 gene via allotopic 
expression. The approach was successful in the mitochondrial deliv-
ery of ATP6 derived from the nuclear transcripts. Besides, trans-
genic mice expressing the mutated gene (single nucleotide change 
equivalent to the human mutation responsible for Neuropathy, 
Ataxia and Retinitis Pigmentosa) displayed performance inferior to 
control mice in four out of seven neuromuscular and motor assays. 
Though the characterization and comparison of the two transgenic 
mice should be completed, these experiments reinforce the notion 
that allotopic expression is efficient in vivo.65
Therefore, our aim was to make the undeniable proof-of- 
principle that: (i) in vivo allotopic expression of human ND4 leads to 
the efficient mitochondrial import and assembly of the protein in CI 
without affecting its activity; (ii) its expression, driven by an AAV2 
vector, impedes vision loss in a LHON rat model by fully preventing 
CI defect due to mutant ND4 expression. We first demonstrated 
that the human ND4 protein, which shares 67% of identity and 84% 
of similarity with the rat protein, can efficiently compete with this 
latter and assemble into a functional rat CI by using two indepen-
dent protocols: (i) The PLA assay39 corroborated in situ interaction 
of human ND4 with ND6 or NDUFS1, two CI proteins. (ii) BN-PAGE 
experiments46 showed that human ND4 (molecular mass of ~54 kDa) 
migrated similarly than NDUFA9, NDUFB8, and NDUFS1, three sub-
units of CI indicating its presence within assembled CI. Importantly, 
human ND4 expression driven by AAV2/2 was sustained for up to 12 
months in about 75% of the total RGC population with no change 
in cell viability or function. This was supported by: (i) eye fundus 
imaging; (ii) optomotor behavior, (iii) RGC number estimation; (iv) CI 
activity assessment in ONs.
The next step was to confirm the effectiveness of AAV2/2-
ND4 treatment in a reliable animal model of LHON. It is well 
known that in some mtDNA diseases, not all mtDNA molecules 
are affected and the extent of heteroplasmy is accountable of 
symptom severity.66 In LHON patients, the ND4 mutation is gen-
erally homoplasmic but some rare cases of heteroplasmy were 
described; for instance in a clinically unaffected member from 
the fifth generation of an Australian pedigree67 and in pedigrees 
of the G11778A LHON mutation from Thailand in which the pro-
portion of mutated mtDNA correlated with visual loss.68 Hence 
to better mimic what happens in LHON patients and permit the 
use of AAV2/2-ND4 to assess its ability to impede RGC loss we 
designed an improved protocol of eye intervention different to 
the one we previously reported:29 an intravitreal injection of a 
plasmid carrying mutant ND4 followed by in vivo ELP and 10 days 
later the same eye was subjected to an intravitreal injection of 
either AAV2/2-ND4 or AAV2/2-GFP. Then, it becomes feasible to 
compare the effect of GFP or human ND4 protein accumulation 
in eyes that express mutant ND4. The benefit of AAV2/2-ND4 for 
RGC integrity was proven by the fact that the ~33% RGC num-
ber reduction in eyes expressing mutant ND4 was prevented in 
eyes subjected to AAV2/2-ND4 injection. This data was in agree-
ment with eyes fundus visualizations and ON immunostaining for 
NF200 which clearly showed that nerve fiber preservation was 
only noticed when rat eyes were treated with AAV2/2-ND4. As 
expected, rats in which eyes possessed optic fiber density com-
parable to controls responded normally to the optomotor test. 
In contrast, animals transduced with GFP consistently showed 
an approximate 40% reduction in their treated eye scores. 
Unquestionably, the final demonstration of AAV2/2-ND4 effec-
tiveness on protection against the deleterious effect of mutant 
ND4 and hence on the achievement of in vivo allotopic expres-
sion is provided by the spectrophotometric measurement of CI 
enzymatic activity in ONs. CI and CV activities were measured in 
ONs from control animals and values obtained were reliable since 
only minor fluctuations were noticed. Consequently, CI activity 
diminution measured in ONs from eyes that expressed mutant 
ND4 reflects compromised mitochondrial function in remaining 
RGC axons. Assessments of CI activity in ONs from eyes subjected 
to AAV2/2-ND4 administration undeniably showed the preserva-
tion of CI function. Even though we did not circumvent the lack of 
a genuine genetic model for LHON, we demonstrated that mutant 
ND4 injury in the model used for testing AAV2/2-ND4 effect was 
identical to the one evidenced previously using in vivo ELP.29 This 
emphasizes the authenticity of mutant ND4 detrimental effect on 
RGC viability. Accordingly, the benefit of human wild-type ND4 
protein in the LHON model was reinforced because the protein 
was capable to protect RGC function durably and safely.
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In conclusion, we provide converging lines of evidence that opti-
mized allotopic expression is safe and efficient in vivo, therefore, the 
clinical trial for LHON patients bearing the G11778A mutation using 
AAV2/2-ND4 was initiated (NCT02064569). The follow-up of enrolled 
subjects will have a strong accent on evaluating safety (lack of adverse 
events related to vector injection) but it can also begin to address the 
potential for benefit in terms of visual function. Clinically meaningful 
improvement including patient’s quality of life will depend on RGC 
functional plasticity.69 Hypothetically, residual RGCs in treated LHON 
patients could optimize their connectivity leading to structural and 
functional reorganization close to the macula. This region is respon-
sible for color and high acuity vision due to the largest concentration 
of cones. A putative rewiring inside the retina may work in concert 
with a cortical plasticity in the visual cortex, recently described in 
asymptomatic LHON carriers.70 At last, if the clinical trial is safe and 
efficacious, the strategy could be extended to other devastating neu-
rodegenerative disorders with mitochondrial etiology from which 
few efficient treatments are available up to date.55
MATeRIAlS AND MeThODS
Adeno-associated viral vectors
The vector used for gene therapy is a recombinant AAV2/2 containing 
the human NADH dehydrogenase 4 (ND4) gene under the control of the 
 cytomegalovirus immediate early promoter in an intron-containing expres-
sion cassette (β globin intron, HBB2), flanked by the viral inverted termi-
nal repeats of the pAAV-IRES-hrGFP vector (Agilent Technologies, Les Ulis, 
France). The human open reading frame (ORF) of ND4 was recoded for the 
34 non universal codons and optimized to achieve high-level expression 
in mammalian cells; in frame with the AUG codon was appended 84 base 
pairs encoding the first 28 amino acids of COX10 corresponding to the mito-
chondrial targeting sequence (MTS). The human growth hormone polyA 
signal originally included in the vector (478 nucleotides) was replaced by 
603 nucleotides of the human COX10 3′ UTR; instead of the full-length 3′UTR 
previously described.29 Indeed, pAAV-IRES-hrGFP can only accommodate 
inserts ≤1.7 kb. The vector leads to the synthesis of the human ND4 protein 
in which three HA1 epitopes are appended at its C-terminal immediately fol-
lowed by two stop codons; the whole ORF was synthesized by GenScript. As 
negative control, the pAAV-IRES-hrGFP was used without ORF but the GFP. 
The AAV2/2-ND4 was manufactured either in the Vector Core of Genethon 
(http://www.genethon.fr/en/); its titer was 1.6 × 1012 VG/ml or the “Centre de 
Production de Vecteurs and the INSERM UMR1089, Nantes” which titer was 
1.6 × 1011 VG/ml. AAV2/2-GFP and AAV2/2-mutant ND4 vectors, also obtained 
from Nantes, had titers of 6.2 × 1011 VG/ml and 8.3 × 1011 VG/ml respectively.
Animals
Male Long Evans rats were used at 8-week old (Janvier, Le Genest Saint Isle, 
France); they were housed two per cage in a temperature-controlled envi-
ronment and 12 hour light/dark cycle. All animal studies were conducted in 
accordance with the guidelines issued by the French Ministry of Agriculture 
and the Veterinarian Department of Paris (Permit number DF/DF_2010_
PA1000298), the French Ministry of Research (Approval number 5575) and 
UPMC/INSERM ethics committees (Authorization number 75–1710).
In vivo electroporation and intravitreal injection of AAV2/2 vectors
The ELP procedure was performed in one eye as previously described.29 After 
dilatation of the pupil with topical 1% tropicamide (CibaVision) and under 
anesthesia with isoflurane (40 mg/kg body weight), the protocol was initi-
ated with the injection in the vitreous body of 20 μg (5 µl) of pAAV-IRES-hrGFP 
plasmid containing the human ND4 gene harboring the G11778A mutation 
and 3 Flag epitopes appended to the last amino acid codon. Next, contact- 
lens-type and needle electrodes were positioned, and square wave pulses 
were delivered by a Square Wave Electroporation System (ECM 830; BTX, 
Harvard Apparatus, Les Ulis, France) as previously described.29 For AAV2/2 
administration, intravitreal injections were performed with 5 µl of vector sus-
pension using an ophthalmic surgical microscope. Supplementary Table S1 
recapitulates the eyes subjected to AAV2/2 administration, vectors, and the 
doses used.
Fundus imaging by confocal scanning laser ophthalmoscopy 
(cSLO)
The Heidelberg Retina Angiograph (Heidelberg Engineering, Dossenheim, 
Germany) is a scanning laser ophthalmoscope (cSLO) which allows imaging 
of eye fundus. To adapt the commercial system to the optics of rodent eyes, 
the 40 mm focal lens of the front objective was replaced by a 25 mm focal 
lens (Linos Optics, Milford, MA). The system allows the examination of nerve 
fiber layer in each cardinal area of rat eyes before treatment and different 
times after vector administration. Images were obtained using the 30° field 
of view and the automatic real-time mode at a sensitivity setting that maxi-
mized the signal/noise ratio; all the cardinal areas of the eye fundus were 
observed, thus, obtaining fiber bundle distribution in the whole retina. The 
built-in software was used for postprocessing the images, including align-
ment, adjustment of contrast, construction of a mean image and/or of a 
composite image, as previously described.36
Optomotor tests
The head-tracking method is based on an optomotor test frequently used in 
rodents.29,37 The protocol yields independent measures of right and left eye 
acuities based on their unequal sensitivities to pattern rotation: right and left 
eyes are most sensitive to counterclockwise and clockwise rotations, respec-
tively.37 Long Evans rats were placed individually on an elevated horizontal 
platform surrounded by a motorized drum (12°/s) in photopic conditions. 
Vertical black-and-white lines of three varying widths, subtending 0.125, 
0.25, and 0.5 cycle/degree (cyc/deg) were presented to the animal and 
rotated alternatively clockwise and counterclockwise, each for 60 seconds. 
Head movements were recorded with a video camera mounted above the 
apparatus; light levels were kept at 240 lux. Animals were scored only when 
the speed of the head turn corresponded to the rotation speed of the stripes. 
Assessments were performed before ocular treatment and monthly after 
the ocular intervention; experimenters were blind to previously recorded 
results, and thresholds were regularly confirmed by more than one observer.
Retinal and optic nerve histology
Retinas or optic nerves were fixed in PBS + 4% paraformaldehyde at 4 °C and 
then cryoprotected by overnight incubation in PBS containing 30% sucrose at 
4 °C. Retinas were embedded in optimal cutting temperature compound (Neg 
50, Richard-Allan Scientific, Villebon-Sur-Yvette, France) and frozen in liquid 
nitrogen. Optic nerves were embedded in a solution of PBS + 7.5% gelatin from 
porcine skin Type A (Sigma-Aldrich, Saint-Quentin Fallavier, France) and 10% 
sucrose and frozen in a 2-methyl-butane solution at −45 °C. Ten micrometer-
thick cryosections of retinas and optic nerves were cut on a cryostat (Microm 
HM550, ThermoScientific, Villebon-Sur-Yvette, France). For immunochemistry, 
retinal sections were rinsed with PBS and treated for 10 minutes with PBS + 
0.1% Triton and then for 1 hour with 1% BSA, 0.1% Triton, and 0.05% Tween 20. 
Next, they were incubated with primary antibody overnight at 4 °C. Sections 
were washed in PBS and incubated with appropriate secondary antibodies 
and DAPI (Sigma-Aldrich) for 2 hours at room temperature. Primary and sec-
ondary antibodies used are shown in Supplementary Table S2. For retinal flat 
mounts, the protocol previously described was followed.8
In situ proximity ligation assay
Duolink Kit (Olink Bioscience, Uppsala, Sweden) is based on in situ PLA, prox-
imity ligation assay technology which allows visualization of protein inter-
actions in fixed tissues.39 In the assay, oligonucleotide-tagged secondary 
antibodies are linked with circle-forming oligonucleotides. If two antigens, 
detected by primary antibodies derived from different species, are in close 
proximity (<40 nm) to each other, after the ligation step of the two linker 
oligonucleotides, the rolling circle amplification using complementary fluo-
rophore-tagged oligonucleotide probes results in fluorescent puncta at the 
site of interaction. The technique has been reported as effective demonstrat-
ing protein interactions in rodent retinal sections.41,42 Assays were performed 
with retinal sections from 4 independent eyes treated with AAV2/2-ND4 
(5 × 109 VG) obtained 3–6 months postinjection or their fellow untreated 
eyes. The manufacturer’s instructions were essentially followed using the dif-
ferent antibodies listed in Supplementary Table S2. Briefly, different mouse 
antibodies against: HA1 epitope, NDUFB6 (complex I subunit), SDHA1 (the 
70-kDa (FP) subunit of complex II) or TOMM20 (mitochondrial translocase 
of the outer membrane) in combination with rabbit antibodies against: ND6 
(complex I subunit), NDUFS1 (complex I subunit), VDAC (outer mitochondrial 
membrane protein), or OPA1 (inner mitochondrial membrane) were used.
13
Efficiency of gene therapy with the mitochondrial ND4 gene for optic atrophy
H Cwerman-Thibault et al.
Molecular Therapy — Methods & Clinical Development (2015) 15003© 2015 The American Society of Gene & Cell Therapy
Microscopic observations
Fluorescence labeling was monitored at the Cellular Imaging Facility of the 
Vision Institute with a confocal laser scanning microscope FV1000 (Olympus) 
and a fluorescence microscope (Leica DM5000 B). Image acquisition was con-
ducted with Olympus Fluoview software version 3.1 and the the MetaVue 
software. Finally, all the images were analyzed with Photoshop and Image J 
softwares.
RNA extraction and RT-qPCR assay
Total RNA from rat retinas were extracted using RNeasy Plus Mini kit from 
Qiagen (Courtaboeuf, France). To ensure the absence of DNA, a treatment 
with RNase-free DNase (Qiagen) and a subsequent cleanup with the RNeasy 
MinElute cleanup kit (Qiagen) were performed. This was confirmed by subject-
ing 10 ng of each RNA preparation to qPCR with human ND4, endogenous 
ATP6 or BRN3A primers. One microgram of total RNA was reverse transcribed 
with oligo-dT using Superscript II Reverse Transcriptase (Life Technologies, 
Saint-Aubin, France). Quantitative PCR reactions were performed using ABI 
7500 Fast (Applied Biosystems, Saint Aubin, France) and the specific primers 
(Life Technologies) listed in Supplementary Table S3. The equivalent of 10 and 
2 ng of cDNAs were used per gene as template for qPCR reactions with Power 
Sybr green PCR Master Mix (Applied Biosystems). Each biological sample was 
subjected to the assay in triplicates per gene; Ct values (number of cycles 
required for the fluorescent signal to cross the background threshold) were 
obtained with the ABI 7500 software (v.2.0.4). To determine the relative mRNA 
amount of each studied gene we used the comparative ΔΔCt method and the 
mitochondrial ATP6 gene as normalizing gene since its mRNA steady-state lev-
els remained almost unchanged in all the samples evaluated.
Western blotting analysis and blue native polyacrylamide gel 
electrophoresis
For whole proteins extracts, single retinas were homogenized in 50 μl of 20 
mmol/l HEPES and 60 mmol/l mannitol (pH 7.2) using a 200 μl micro-hand-
driven glass–glass potter at 4 °C. Large cellular debris was spun down by a 
low speed centrifugation (1,000 g for 5 minutes at 4 °C) and supernatants 
were subjected to protein quantification (Bradford reagent). Fifteen and 
30 µg of protein extracts from: four control retinas and four retinas which 
received AAV2/-ND4 intravitreally were denaturated at 94 °C for 15 minutes, 
resolved in 12% SDS-PAGE and transferred to a PVDF membrane. Membranes 
were probed with antibodies against HA1 epitope, NDUFA9, NDUFB8, ATP 
synthase subunit α and β-actin (Supplementary Table S2). Immunoreactive 
bands were visualized with appropriate secondary antibodies coupled to 
horseradish peroxidase (0.1 mg/ml) (Supplementary Table S2) followed 
by  detection with Pierce ECL Plus Western Blotting Substrate (Pierce, 
ThermoScientific, Villebon-Sur-Yvette, France). Apparent molecular mass of 
each protein was estimated by comparing the electrophoretic properties of 
each specific signal in the immunoblots with the “PageRuler Plus Prestained 
Protein Ladder” (Pierce Protein Biology products, ThermoScientific).
For blue native polyacrylamide gel electrophoresis (BN-PAGE) mitoplasts 
isolation was adapted from the report of Calvaruso et al.46 Briefly, after careful 
dissection, retinas were kept frozen and samples were prepared at ice-melting 
temperature by homogenization of 8 retinas using a 1 ml hand-driven glass–
glass potter in 1 ml of ACBT buffer (aminocaproic acid 1.5 mol/l; Bis-Tris 75 
mmol/l; pH 7). 100 µl of β-lauryl-maltoside 20% (Biorad, Marnes-la-Coquette, 
France) were added to allow the isolation of respiratory chain complexes. The 
mixture was kept on ice for 10 minutes and then centrifuged for 30 minutes 
at 14,000 rpm. The protein content of the supernatant was measured with the 
BCA protein assay kit (Pierce ThermoScientific) and then kept at −20 °C until 
use. BN-PAGE 5–15% gradient gels were casted and then loaded with 200 µg 
of proteins. To perform two-dimensional blue native/SDS electrophoresis, 
lanes were cut out of the first dimension and incubated with 1% SDS and 1% 
β-mercaptoethanol for one hour at room temperature. The gel strip was placed 
at the top of glass plates in order to poor the SDS gel (4% for stacking and 10% 
for separation). Next, standard western blotting protocols for SDS gels were 
applied.46 Immunodetection was performed using primary antibodies against 
proteins of the respiratory chain (Supplementary Table S2). To reuse mem-
branes, the antibody was removed with the Re-Blot Plus Western Blot Strong 
Antibody Stripping Solution (Millipore, Molsheim, France).
Tissue homogenate preparation and respiratory chain enzyme 
assays
Optic nerves were rapidly collected and kept frozen (−80 °C). CI and CV 
activities were measured using a Cary 50 UV-Vis spectrophotometer 
(Agilent  Technologies) as described for retinas and ONs from rodents.48 CI 
activity values were either normalized by CV or converted to specific activities 
(expressed as nanomoles of oxidized NADH/minute/mg protein) after pro-
tein quantification by the Bradford method. All chemicals were of the highest 
grade from Sigma-Aldrich.
Statistical analyses
Values are expressed as means ± standard error of the mean. Statistical 
analyses were performed with the GraphPad Prism 6.0 software assuming a 
confidence interval of 95%. Data collected for all the independent observa-
tions were compared using the non parametric significance test of Mann–
Whitney (*≤0.05, **≤0.01, and ***≤0.005).
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